Aarkstore - Ophthalmic Drugs; Data, Analysis and Forecasts t

1. Category : Healthcare Aarkstore - Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

2. Aarkstore - Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

3. Summary Which ophthalmic drugs lead the market in 2013? Will the same drugs be as successful in 2018? How will this landscape change across the next 10 years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading GMR Data’s new ‘Ophthalmic Drugs; Data, Analysis and Forecasts to 2024’ report, you can stay ahead of your competition. It really is that simple. GMR Data forecasts that the global ophthalmic drugs market will reach $9.7bn by 2024. The US market growth will be slow compared to other markets predominantly due to major drug patent expiry and generic erosion. For example;

4. • Xalabrands from Pfizer used for treatment of Glaucoma expired in the US in March 2011. • Azopt by Alcon used for treatment of Glaucoma expired in the US in October 2012. • Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013. • Restasis from Allergan used for treatment of Dry eye will expire in the US in May 2014. • Travatan by Alcon used for treatment of Glaucoma will expire in the US in 2014. • Combigan by Allergan used for treatment of Glaucoma will expire in the US in 2022. • Lucentis from Novartis used for treatment of Retinal Disorder will expire in the US in June 2020. Restasis by Allergan is the market-leading drug in the ophthalmic market with sales of $1bn across 2013. Will it be able to see off the competition for the next 5 years? The next 10 years? This report tells you. With an assessment of the leading markets, such as the US, and EU, GMR Data examine how Germany and France are the largest EU markets and what % of the global market they make up. Which other countries contribute most? This report tells you in a concise, focused and easily accessible format.

5. Table of Contents: 1. Executive Summary 1.1 Ophthalmic Drugs Market Review 1.2 Chapter Breakdown 1.3 Research and Analysis Methods 2. Causes and Treatments of Ophthalmic Disorders 2.1 Human Eye 2.2 Structure of Human Eye 2.3 Major Global Causes of Blindness & Vision Impairment 2.3.1 Primary Causes of Blindness 2.3.2 Primary Causes of Visual Impairment 2.3.3 Geographic Breakdown of Global Blindness and Vision Impairment 2.3.4 Primary Factors Contributing to Visual Impairment 2.4 The Most Common Type of Eye Disorders 2.4.1 Cataracts 2.4.2 Glaucoma 2.4.3 Retinal Detachment

6. List Of Tables Table 2.3 WHO Estimation of Blind/Vision impaired Population Globally, 1975-2010 Table 2.3.1 Breakdown of Global Blindness Cases as per Eye Disease Table 2.3.2 Breakdown of Global Vision Impairment Cases as per Eye Disease 2010 Table 2.4.2.1 Major Glaucoma Drugs in the Market Table 2.4.4.1 Major Ophthalmic Anti-allergy Drugs in the Market Table 2.4.5.1 Major Ophthalmic Anti-inflammatory Drugs in the Market Table 2.4.6.1 Major Ophthalmic Anti-infective Drugs in the Market Table 2.4.7.1 Major Diabetic Retinopathy Drugs in the Market Table 2.4.8.1 Major Dry Eye Treatment Drugs in the Market Table 2.4.9.1 Major wet-AMD Treatment Drugs in the Market

7. List Of Figures Figure 2.3 WHO Estimation of Blind/Vision impaired Population Globally, 1975-2010 Figure 2.3.1 Breakdown of Global Blindness Cases, as per Eye Disease, 2010 Figure 2.3.2 Breakdown of Global Vision Impairment Cases as per Eye Disease 2010 Figure 2.3.3 Breakdown of Global Blindness and Vision Impairment by Geography 2012 Figure 2.3.4 Projection of Global Blind People aged 50+ by 2019 Figure 3.2.1 Market Size and Forecast – Global Ophthalmology Pharmaceuticals Sales ($/m) Figure 3.2.2 Global Ophthalmology Pharmaceuticals Drug Market Share 2014 to 2024 – (%) Figure 4.2.1 Population of over 60’s in Selected Nations 2009 (millions) Figure 4.2.2 Market Share of Major Companies – by Sales of Anti-Glaucoma Drug 2012

8. Related Reports • Generic Drugs Market in Japan 2015-2019 • Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Lupus Erythematosus-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

9. Related Reports • Malaria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Pharmaceuticals & Healthcare Market Research Reports

10. Ophthalmic Drugs; Data, Analysis and Forecasts to 2024 Published: Sep 2014 | 160 Pages GMR Data forecasts that the global ophthalmic drugs market will reach $9.7bn by 2024.

11. Contact Us Office Office No. - 809, 8th Floor, B-Wing, Mahaavir Icon,  Plot No.- 89 & 90, Sector-15, CBD-Belapur, Navi Mumbai – 400614,  Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit : http://www.aarkstore.com OR Mail us at : contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news